1Pruss TP,Stoiβnig H,Radhofer Welte S,et al.Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam[].Postgraduate Medical Journal.1990
2Olkkola KT,Brunetto AV,Mattila MJ.Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents[].Clinical Pharmacokinetics.1994
3Nuutinen LS,Laitinen JO,Salomaki TE.A risk-benefit appraisal of injectable NSAIDs in the management of postoper-ative pain[].Drug Safety.1993
4Kullich W,Klein G.Influence of the nonsteroidal anti-inflammatory drug lornoxicam on the secretion of the endogenous opiate peptides dynorphin andβ-endorphin[].Aktuelle Rheumatologie.1992
5Detlef ER,Morten A,Diet mars.A comparison of patient-con-trolled analgesia withlornoxicam versus morphine in patients un-dergoing lumbar disk surgery[].Anesthesia and Analgesia.1998
6Norholt SE,Sindet-Pedersen S,Larsen U,et al.Pain control after dental surgery: a double blind, randomised trial of lornoxicam versus morphine[].Pain.1996
7Berg J,Christoph T,Widerna M,et al.Isoenzyme-specific cyclooxygenase inhibitors:a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac6[].Journal of Pharmacological and Toxicological Methods.1997
